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Summary
Background. Patients with venous thromboembolic disease may
present with different clinical manifestations. Factor V Leiden mutation
leading to resistance to activated protein C is associated with a seven-
fold increased risk for presenting with deep-vein thrombosis. It is
not yet established whether carriers of the mutation have a similarly
increased risk for manifesting with pulmonary embolism.
Methods. From an Anticoagulation Clinic monitoring coumarin
therapy, a consecutive series of patients with a first thromboembolic
event (objectively proven by current radiological methods) were
enrolled. All patients were interviewed and blood was drawn for geno-
typing. From the hospital charts and the personal interview, informa-
tion was obtained on acquired risk factors and the signs and Symptoms
on hospital admission.
Results. 45 patients presented with Symptoms of pulmonary embo-
lism only, 211 had only Symptoms of deep-vein thrombosis whereas 23
had clinical features of both. In about half of the patients acquired risk
factors for venous thromboembolism were present which did not differ
between the three groups of patients. Recent surgery had been per-
formed more often in patients presenting with pulmonary embolism
than in other patients (33.3% vs. 18.5%, p <0,05). Factor V Leiden was
present in 9% of the patients presenting with pulmonary embolism
(relative risk: 3.3 95% CI: 1.0-10.6) and 17% of the patients presenting
with deep-vein thrombosis (relative risk: 6.9 95% CI: 3.6-12.8). The
prevalence of factor V Leiden was intermediate in patients with both
clinical characteristics.
Condusion. These data suggest that patients with venous throm-
boembolism have different clinical presentation depending on the risk
factor profile. Factor V Leiden may preferentially lead to manifest
deep-vein thrombosis. Differences in structure of venous thrombi could
underlie differences in embolic tendency.
Introduction
Patients with venous thromboembolic disease may present with
different clinical manifestations. Pulmonary embolism without signs
or Symptoms of the underlying deep-vein thrombosis is one end of
the spectrum while deep-vein thrombosis without clinical features of
pulmonary embolism represents the other. At present, it is not known
whether there are specific factors that determine how venous throm-
boembolism becomes clinically apparent.
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Intensive clinical, epidemiological and laboratory research has led to
the identification of several hereditary and acquired conditions predis-
posing to deep-vein thrombosis (1). The most common genetic risk
factor is the recently described factor V Leiden, a single point mutation
in the factor V gene (2), causing resistance to activated protein C (3),
which increases the risk for deep-venous thrombosis about seven-fold
(4).
Since venous thromboembolism is considered äs one single disease
entity, it is assumed that the hereditary and acquired risk factors in
patients presenting with deep-vein thrombosis, are similar to those in
patients presenting with pulmonary embolism. The aim of the present
study is to validate this assumption by a comparison of the risk factor
profiles in patients with different clinical manifestations of venous
thromboembolism. As factor V Leiden is the most frequent inherited
disorder of the anticoagulant System, we will focus on the association of
this factor with the different clinical presentations of venous throm-
boembolic disease.
Methods
Setting
In the Netherlands, all patients requiring oral anticoagulant treatment are
referred to an Anticoagulation Clinic for outpatient monitoring, each of which
serves a well defmed geographical area (5). To investigate the distribution of
risk factors in patients with different clinical manifestations of venous throm-
boembolism, we divided the patients referred to the Leiden Anticoagulation
Clinic in three study groups. In the first group, patients with deep-vein throm-
bosis without signs or Symptoms of pulmonary embolism were included.
Patients with pulmonary embolism without any sign or symptom of the under-
lying deep-vein thrombosis were assigned to the second group. The third group
consisted of patients who presented with the clinical manifestations of both
deep-vein thrombosis and pulmonary embolism.
Patients with Symptoms ofDeep-Vein Thrombosis only
In a previous case- control study, embedded in three Anticoagulation
Clinics, consecutive paüents with a first episode of deep-vein thrombosis had
been included. Patients over 70 years of age and patients with a malignancy
were excluded. Each patient was interviewed in the outpatient department after
a median time of 19 months since diagnosis. During this visit, blood was drawn
to determine the presence of the factor V Leiden mutation by genotyping
according to established laboratory procedures, described in detail elsewhere
(2). Results of this study in patients with deep-vein thrombosis have been
reported earlier (4,6).
In the present analysis, only patients treated in the Leiden Anticoagulation
Clinic were included of whom detailed Information on their hospital admission
was available. These patients had been diagnosed by ultrasound or venography
in the period January 1988-December 1992. Available data included the clini-
510
II
cal history, physical examination, imagmg techniques and the disease course.
From the medical records and the personal interview, we obtained Information
on the presence or absence of acquired risk factors, defmed äs recent surgery
(<2 months before admission), hospitalisation without surgery, prolonged
bedrest (>2 weeks within 30 days of the admission date) at home, post partum
periods (within 30 days of the admission date), and recent trauma (<3 weeks) of
the involved limb (1,7).
Patients with Symptoms of Pulmonary Embolism only
In the period 1988-1989, a consecutive series of patients who had been
treated in the Leiden Anticoagulation Climc for pulmonary embolism without
clinical signs or Symptoms of deep-vein thrombosis were considered. For these
patients, we reviewed the evidence on which the diagnosis of pulmonary embo-
lism was based. Only patients with an objectively confirmed diagnosis, i.e. a
positive pulmonary angiography or a (Ventilation) perfusion lungscan with
defects indicating high- probability for pulmonary embolism were included in
the present analysis. Of these patients, laboratory procedures and collection of
relevant Information were established in the same way äs for patients with
deep-vein thrombosis mentioned above.
Patients with Symptoms ofboth Deep-Vein Thrombosis and
Pulmonary Embolism
In all patients with deep-vein thrombosis included in the first group, the
clinical history was evaluated for signs or Symptoms indicating the presence of
a concomitant pulmonary embolism. Since these patients already suffered from
an objectively confirmed deep-vein thrombosis, rendering a high prior prob-
ability of ehest Symptoms to be due to pulmonaiy embolism, the diagnostic
criteria for pulmonary embolism mentioned above were extended. Patients with
paroxysms or acute onset of dyspnoe, ehest pain of pleuritic nature or a pleural
friction rub on physical examination were also considered having a proven
pulmonary embolism when imaging techniques were not available. These
patients presenting with deep-vein thrombosis complicated by a clinically
manifest pulmonary embolism, were analysed äs a separate group.
Control Subjects
To compare the distribution of risk factors for venous thromboembolism in
the three patient groups to the normal population and to calculate odds ratios äs
a measure of relative risk, a control group was included. It consisted of the
control subjects of the original case control study, who were individuals
without a history of venous thromboembolism (4). In these individuals, the
presence of acquired risk factors was evaluated by use of a questionnaire, and
blood samples for factor V Leiden determination were drawn in the same
Session.
Statislical Analysis
Between the various study groups, the distribution of acquired risk factors
and factor V Leiden were compared using the x2-statistic. Exposure odds ratios
were calculated äs estimates of relative risks for thromboembolic disease. Odds
ratios were adjusted for age and sex in a logistic regression model. 95%-
Confidence intervals (95% CI) for the odds ratios were derived from the
Standard error of the coefficient of the model.
Results
A total of 55 patients were identified who had been treated with oral
anticoagulants for a diagnosis of pulmonary embolism without signs or
Symptoms of deep-vein thrombosis. On revision, ten of these patients
were excluded because the diagnosis was not objectively proven,
leaving 45 patients for analysis. Of the 234 patients with deep-vein
thrombosis, 23 (10%) were diagnosed with concomitant pulmonary
Table l Age and sex distributions of patients classified on their clinical
presentation
PE only DVT with PE DVT only Controls
number
mean age (yrs)
Sex (F/M)
45
456
13/32
23
413
10/13
211
41.2
121/90
474
441
272/202
PE only, patients with only Symptoms of pulmonary embolism
DVT only, patients with only Symptoms of deep-vein thrombosis
DVT with PE, patients with Symptoms of both deep-vein thrombosis and pulmonary
embolism
embolism during hospital admission. All other 211 patients lacked
signs or Symptoms indicating pulmonary involvement. Age and sex
distributions of the study groups are shown in Table l. The female/male
ratio in the patients presenting with pulmonary embolism was signifi-
cantly lower than in the other study groups.
The risk f actor profiles of patients presenting with pulmonary embo-
lism only and patients with deep-vein thrombosis with and without con-
comitant pulmonary embolism are presented in Table 2. The prevalence
of the factor V Leiden mutation was lowest in patients with Symptoms
of pulmonary embolism only and highest in patients with deep-vein
thrombosis only, whereas the prevalence was in-between in patients
with Symptoms of both. When confined to the subgroups of patients
without acquired risk factors, factor V Leiden was present in 22.7%
(25 out of 110) of the patients presenting with deep-vein thrombosis
Table 2 Comparison of risk factors between patients classified on their
clinical presentation
PE only DVT with PE DVT only
Risk factor (n=45) (n=23) (n=211)
none
factor V Leiden
acquired
recent surgery
hospitalization
immobilization
postpartum
trauma
23(51 1%)
4 (8 9%)
19(422%)
15
1
-
1
2
12 (52.2%)
3(130%)
9(391%)
3
1
-
1
4
85 (40 3%)
37 (17 5%)
101 (47 9%)
39
11
6
15
30
Ii
PE only patients with only Symptoms of pulmonary embolism,
DVT only patients with only Symptoms of deep-vein thrombosis
DVT with PE patients with Symptoms of both deep-vein thrombosis and pulmonary
embolism
Totais can add up to more than 100% smce patients can have more than one risk
factor
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Table 3 Relative risks of factor V Leiden in patients with pulmonary embo-
lism and deep-vein thrombosis
factor V Leiden
Group (n)
controls (474)
PE only (45)
DVTonly(211)
present
14
4
37
absent
460
41
174
RR (95% Cl)
1
3.3 (1.0-10.6)
6.9 (3.6-12.8)
PE only: patients with only Symptoms of pulmonary embolism
DVT only: patients with only Symptoms of deep-vein thrombosis
95% Cl: 95% confidence interval.
Relative risks (RR) were estimated with exposure odds ratios and adjusted for age
and sex by logistic regression.
only, and in 11.5% (3 out of 26) of the patients with pulmonary
embolism only (χ2 = 1.12, df = l, p = 0.28). Three patients presenting
deep-vein thrombosis and one patient with clinical features of both
deep-vein thrombosis and pulmonary embolism were homozygous
carriers of the trait. Neither in the control group nor in the patients
presenting with pulmonary embolism, homozygous carriers could be
identified.
Recent surgery had been performed in 33.3% (15 out of 45) of
the patients presenting with pulmonary embolism only and in 18.5%
(39 out of 211) of the patients presenting with deep-vein thrombosis
only (χ2 = 4.9, df = l, p = 0.03). In patients with clinical features of
both this percentage was 13.0 (3 out of 23).
To further analyze the contribution of the factor V Leiden mutation
to the different clinical manifestations of venous thromboembolic
disease, exposure odds ratios were calculated (Table 3). Factor V
Leiden increased the risk for pulmonary embolism three-fold
(OR = 3.3, 95%CI 1.0-10.6). The risk for deep-vein thrombosis was
seven-fold (OR = 6.9, 95%CI 3.6-12.8) increased in the carriers of
factor V Leiden.
Discussion
The overall percentage of patients with acquired risk factors for
venous thromboemblism did not differ between the three study groups.
This supports the findings in a recently reported series of patients with
manifest deep-vein thrombosis in which also no association was found
between various acquired risk factors and the occurrence of concomi-
tant pulmonary embolism (7). These authors, however, did not investi-
gate hereditary disorders predisposing to venous thromboembolism,
nor did they include patients presenting with pulmonary embolism
without signs or Symptoms of deep-vein thrombosis.
In our study, recent surgery had been performed in a higher percent-
age of patients presenting with pulmonary embolism. There was no dif-
ference in the frequency of recent surgery between patients presenting
with deep-vein thrombosis with or without clinically manifest pulmo-
nary embolism. Although there is no obvious explanation yet, this find-
ing demonstrates that significant differences in risk factors emerge
between patients with venous thromboembolism when they are classi-
fied on their clinical manifestations. This notion is enforced by the
remarkable sex difference between the study groups.
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We expected that factor V Leiden would be more prevalent in the
patients presenting with pulmonary embolism since resistance to acti-
vated protein C may lead to more extensive venous thrombosis and a
subsequently higher risk for pulmonary embolism. Contrary to this
expectation, the prevalence of factor V Leiden was lower in patients
with the clinical presentation of pulmonary embolism only. The age
and sex adjusted risk for presenting with pulmonary embolism in
carriers of the trait was "only" three-fold increased in comparison with
the seven-fold increased risk for deep-vein thrombosis. Partly in line
with these observations are the results of a recently reported study
investigating the prevalence of activated protein C (APC) resistance in
an unselected series of patients presenting with pulmonary embolism
without clinical signs or Symptoms of deep-vein thrombosis (11). In
patients with an objectively confirmed diagnosis, the prevalence of
APC resistance was 5.5% which was only slightly different from the
prevalence of 4.0% found in the patients in whom the diagnosis was
ruled out. In this study, however, no DNA analysis was performed to
confirm the presence of factor V Leiden in APC resistant patients and
unfortunately no subdivision was made äs to underlying disease.
It has been shown that thrombi confmed to the calf veins pose
limited embolic risk (8,9,10). How the location of a thrombus affects
its embolic potential is unknown, although it is suggested that size is an
important determinant (12). In analogy, it may be postulated that the
various etiologic mechanisms (e.g. genetic background and stasis of
Wood flow) lead to venous thrombosis with different embolic and
obstructive potential, similar to the differences in red and white arterial
thrombosis. Our findings support the hypothesis that venous thrombi
caused by various etiologic mechanisms have different structure and
factor V Leiden leads to thrombi with smaller embolic risk.
An objection to our findings may be diagnostic misclassification. It
is unlikely, however, that this can explain our observations since only
patients who satisfied current, stringent, radiological criteria for pulmo-
nary embolism were included in the study, and the positive predictive
value of a high probability result of a ventilation-perfusion lungscan is
almost 90% (12, 13). A substantial number of patients, classified äs
having deep-vein thrombosis only, will have had silent pulmonary
embolism. Also, a high proportion of patients presenting with pulmo-
nary embolism, will have had asymptomatic deep-vein thrombosis
when investigated by venography. From a methodological point of
view this will only have deflated the risk differences between the study
groups and does not argue against the hypothesis. Furthermore, there
are relevant arguments to support our objective to compare risk factor
profiles in patients with different clinical manifestations of venous
thromboembolism. Clinically manifest pulmonary embolism is still
considered the most serious (i.e. lethal) presentation of venous throm-
boembolism. It also remains an absolute indication for anticoagulant
treatment, whereas some cases of deep- vein thrombosis (e.g. confmed
to the calf veins) will not be treated. The concerns about the impact of
risk factors on mortality and morbidity of venous thromboembolic
disease are directly related to the possible occurrence of a clinically
manifest pulmonary embolism. The findings in our study suggest that
results from studies on risk factors in patients with deep-vein thrombo-
sis may not automatically be applied to patients presenting with pulmo-
nary embolism.
A high percentage of patients in our study groups did not have an
identifiable risk factor for the occurrence of venous thromboembolic
disease. As the factor V Leiden mutation is the most frequent inherited
disorder of the anticoagulant System, it is unlikely that a large propor-
tion of patients without risk factors will have had other hereditary
thrombotic disorders (i.e. protein C, S or antithrombin deficiencies). In
fact, only one patient presenting with pulmonary embolism only was
identified äs protein C deficient by DNA analysis. It might be possible,
however, that future research will identify new coagulation disorders in
these patients.
The recent identification of factor V Leiden and its high prevalence
in the general population has provided new elements for the discussion
on prevention and management of venous thromboembolism (15, 16,
17). From a clinical and public health perspective, the concern should
focus on the occuirence of pulmonary embolism äs a potentially lethal
manifestation of venous thromboembolic disease (l, 16). The present
study indicates that risk factors may have different impact on venous
thrombotic and embolic disease.
References
1. Weinmann EE, Salzman EW. Deep- vein thrombosis. N Engl J Med 1994;
331:630-41.
2. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde
H, van der Velden PA, Reitsma PH. Mutation in Wood coagulation associ-
ated with resistance to activated protein C. Nature 1994; 369: 64-7.
3. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a
previously unrecognized mechanism characterized by poor anticoagulant
response to activated protein C: prediction of a cofactor to activated protein
C. Proc Natl Acad Sei USA 1993; 90:1004-8.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina
RM. Venous thromboembolism due to poor anticoagulant response to
activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:
1503-6.
5. Loeliger EA, van Dijk- Wierda CA, van den Besselaar AMHP, Broekmans
AW, Roos J. Anticoagulant therapy and the risk of bleeding; organiza-
tional infrastructure. In: Meade TW, ed. Anticoagulants and myocardial
infarction; a reappraisal. Chicester, John Wiley and sons, 1984:157.
6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of
thrombosis in patients homozygous for factor V Leiden (activated protein C
resistance). Blood 1995; 85: 1504-8.
7. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history
of venous thrombosis. In: Hemostasis and Thrombosis: basic principles and
practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. 3rd ed.
Philadelphia; J B Lippincott 1994: 1275-96.
8. Monreal M, Ruiz J, Olazabal A, Alias A, Roca J. Deep venous thrombosis
and the risk of pulmonary embolism. Chest 1992; 102: 677-81.
9. Moser KM, Le Moine JR. Is embolic risk conditioned by location of deep
venous thrombosis? Ann Int Med 1981; 94:439-44.
10. Philbrick JT, Becker DM. Calf deep venous thrombosis: a wolf in sheep's
dothing? Arch Intern Med 1988; 148: 2131-8.
ll.Desmarais S, de Moerloose P, Reber G, Minazio A, Bounameaux H.
Resistance to activated protein C in an unselected population of patients
with pulmonary embolism. Lancet 1996; 347: 1374-5.
12. Hüll RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G,
Gill GJ, Turpie AG, Doyle DJ, Buller HR, Raskob GE. Pulmonary angio-
graphy, Ventilation lung scanning, and venography for clinically suspected
pulmonary embolism with abnormal perfusion lung scan. Ann Int Med
1983; 98: 891-9.
13. Quinn DA, -Thompson T, Terrin ML, Thrall JH, Athanasoulis CA,
McKusick KA, Stein PD, Haies CA. A prospective investigation of pulmo-
nary embolism in women and men. JAMA 1992; 268:1689-96.
14. Hüll RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR,
David M, Coates G. Diagnostic value of Ventilation- perfusion lung
scanning in patients with suspected pulmonary embolism. Chest 1985; 88:
819-28.
15. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C äs a
pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer ML, Eisenberg PR,
Miletich JP. Mutation in the gene coding for coagulation factor V and the
risk of myocardial infarction, stroke, and venous thromboembolism in
apparently healthy men. N Engl J Med 1995; 332: 912-7.
17. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal
FR. Increased risk of venous thrombosis in oral- contraceptive users who
are carrier of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
Received February 22,1996 Accepted after resubmission June 19,1996
513
